Part 1: The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements
Welcome to The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements online access. This course was originally developed for and recorded for physicians under DATA2000, and provides 8 hours of education needed for prescribing buprenorphine in an office-based treatment setting. Acknowledgement: This product was recorded prior to CARA legislation and will be updated by Spring 2017. More information on waiver requirements can be found below.
To begin the online portion of the course, please log in to your right and locate the box that says Module 1. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password.
This 8-hour online course combines modules from our blended course and Video On-Demand captured on October 5, 2016 in Washington, DC.
All online modules and quizzes must be completed before moving on to Video On-Demand. Detailed instructions for completing the online portion of the course can be found under the tab titled "Course Instructions."
After completing the online modules, Videos On-Demand, corresponding quizzes, and applicable evaluations, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.
Overview of Legislation
Physicians
The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.
Nurse Practitioners & Physician Assistants
Section 303 of the Comprehensive Addiction and Recovery Act (CARA), signed into law by President Obama on July 22, 2016, made several changes to the law regarding office-based opioid addiction treatment with buprenorphine. One of these changes is that prescribing privileges have been expanded to nurse practitioners (NPs) and physician assistants (PAs) for five years (until October 1, 2021).
HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.
NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is in the process of developing multiple 16-hour training course options and formats, including collaborations with:
- 24-Hour Buprenorphine Curriculum Collaborative with the American Association of Nurse Practitioners (AANP) and the American Academy of Physician Assistants (AAPA)
- Clinical Tools, Inc
- Provider's Clinical Support System for Medication-Assisted Treatment (PCSS-MAT)
The ASAM Treatment of Opioid Use Disorder Course: Waiver Qualifying Training has been made available in part by an unrestricted educational grant from Indivior PLC.
- Locate the box on the right that says “Module 1" and click “View Web Content On-Demand"
- Locate the box on the right that says “Certificate code" and enter the code given upon completion of Module 1 Part 1
- Continue to Module 1 Part 2 and Module 1 Part 3
- Once you have completed the entire module, locate the box called “Module 1 Quiz" and choose “Take Quiz"
- After you have completed Module 1 Quiz, continue to modules 2 and 3
- View the videos On-Demand and complete the associated quizzes
- Successful completion of the post-test is required to earn AAPA Category 1 CME credit. Successful completion is defined as a cumulative score of at least 70 percent correct.
- When you complete all modules, quizzes, and evaluation you will be able to claim CME Credit through the ASAM e-Learning Center
Learners will be able to:
- Apply for a wavier to prescribe buprenorphine to their patients with opioid use disorders
- Identify and assess patients who are appropriate for treatment with medications
- Have specific knowledge concerning the use of medications to manage patients with addiction involving opioid use
- Discuss the psychiatric and medical co-morbidities associated with opioid addiction
- Physicians, nurse practitioners, and physician assistants who wish to obtain a waiver to prescribe buprenorphine in office based treatment of opioid use disorders.
- Clinicians and healthcare team members working with providers who prescribe buprenorphine in office-based treatment of opioid use disorders.
The ASAM National Practice Guidelines for the Use of Medications in the Treatment of Addiction Involving Opioid Use: Click here to view ASAM's newly released National Practice Guideline.
Prescribers Clinical Support System for Medication Assisted Treatment - A national training and mentoring project developed in response to the prescription opioid misuse epidemic and the availability of newer pharmacotherapies to address opioid dependence.
- Mentoring for those providing care for opioid dependent individuals available at no cost to all interested providers. Click here.
- Clinical Tools (clinical guidances, sample forms including: patient information, intake forms, treatment agreements, induction forms, TIPs and more). Click here.
SAMHSA Buprenorphine website: Click here to access SAMHSA's website for more information on buprenorphine prescribing. For questions on licensure, DEA-X number etc., please call 866-287-2728 or email info@buprenorphine.samhsa.gov.
DATA Physician Locator: Click here for SAMHSA's physician locator.
Waiver Notification Form: Click here for more information from SAMHSA on how to obtain a waiver and download a waiver notification form.
Agency for Healthcare Research and Quality: Click here for more information from the Agency for Healthcare Research and Quality.
National Institute on Drug Abuse: Click here to visit NIDA's website.
NIDA Buprenorphine Suite of Blending Products: Click here to access NIDA's buprenorphine training for multidisciplinary addiction professionals.
Drug Enforcement Administration: Click here to visit the DEA's website.
A Guide for Law Enforcement on Buprenorphine: Click here to read an article from Huffington Post on Methadone and Buprenorphine.
Handbook of Office-Based Buprenorphine Treatment of Opioid Dependence: Click here for a book by John A. Renner, Jr. and Petros Levounis on treating those with opioid dependence.
How To Fill Out Your NOI Form: Click here for a step-by-step video guide on how to fill out your NOI form. Provided by the American Academy of Addiction Psychiatry.
Daniel P. Alford
MD, MPH, FACP, DFASAM
Dr. Daniel P. Alford is an Associate Professor of Medicine, Assistant Dean of CME and Director of the Safe and Competent Opioid Prescribing Education (SCOPE of Pain) program at Boston University School of Medicine. He is a diplomate in Addiction Medicine by the American Board of Addiction Medicine (ABAM).
He is director of the Clinical Addiction Research and Education Unit medical director of the Office-Based Opioid Treatment (OBOT) program and of the Massachusetts Screening, Brief Intervention, Referral to Treatment Training and Technical Assistance (MASBIRT TTA) program and former program director for the Addiction Medicine Fellowship program at Boston Medical Center (BMC). Since 2001 he has served as the course director of the Chief Resident Immersion Training (CRIT) Program in Addiction Medicine: Improving Clinical and Teaching Skills for Generalists funded by NIDA. He is president of the Association for Medical Education and Research in Substance Abuse (AMERSA). In 2011, he was recognized as a Champion of Change by the White House. In 2014 he received the Health Education Award from the American Medical Association.
Edwin A. Salsitz
MD, DFASAM
Dr. Edwin A. Salsitz has been an attending physician at Mount Sinai Beth Israel, Department of Psychiatry and Behavioral Sciences, since 1983, and is an Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai. He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project. Dr. Salsitz is certified by the American Board of Addiction Medicine (ABAM), as well as by the Board of Internal Medicine and Pulmonary Disease. He lectures frequently and has been published on a variety of addiction medicine topics.
Dr. Salsitz is a course director for ASAM sponsored buprenorphine trainings, and is a mentor in the PCSS-MAT and PCSS-O mentoring programs. He has co-chaired the ASAM Review Course, the ASAM Common Threads Course, the ASAM State of the Art Course and is a reviewer for the Journal of Addiction Medicine. Currently Dr. Salsitz is the chair of the ASAM REMS ER/LA Opioids committee. Dr. Salsitz is a member of the ASAM CME committee and Chair of the New York Society of Addiction Medicine CME and Education committee. He is the recipient of the 2014 ASAM Annual AwardDr. Salsitz is a member of the Medical Advisory Panel, for the New York State Office of Alcohol and Substance Abuse Services.
Sarah Bagley
MD
Sarah Bagley, MD, is an attending in the Departments of Medicine and Pediatrics at Boston Medical Center. Sarah completed a Combined Residency in Internal Medicine and Pediatrics at Brown and then an Addiction Medicine Fellowship at Boston University. Her clinical and research interest are related to the impact of substance use on families and in the treatment of adolescents with substance use disorders.
Jeffrey Baxter
MD
Jeff Baxter, MD, is an Associate Professor of Family Medicine and Community Health at the University of Massachusetts Medical School. Dr. Baxter completed a fellowship in Addiction Medicine at the Boston VA Medical Center, and is board certified in Family Medicine and Addiction Medicine. He currently serves as the Chief Medical Officer for Spectrum Health Systems Addiction Treatment Services, overseeing inpatient, outpatient and residential divisions.
Colleen LaBelle
BSN, RN-BC, CARN
Colleen LaBelle has certifications in addiction nursing and HIV with over 20 years of clinical experience in HIV and addiction, and co-authored a publication in the Journal of General Internal Medicine, “Treating Homeless Opioid Dependent Patients with Buprenorphine in an Office-based Setting." She was instrumental in the start up of the OBOT Program in the BMC Primary Care Clinic, which manages over 450 active patients with buprenorphine. This program provides buprenorphine treatment for patients in primary care, homeless, HIV, Family Medicine, OB, and support to the affiliated community health centers. She is the program director of the STATE OBOT B (State Technical Assistance, Treatment Expansion of Buprenorphine) working with 14 community health centers implementing a nurse care manager model for the expansion of buprenorphine. Since 2003, Ms. LaBelle has served as Faculty for the buprenorphine certification course of the American Society of Addiction Medicine. She frequently gives presentations on buprenorphine and provides consultation and technical assistance on- and offsite and by telephone. She oversees the MDPH buprenorphine list-serve and provides liaison for MDPH supported buprenorphine training, education and start-up in Massachusetts. She speaks on a local and national level, and has been a part of the SAMHSA Summit on Buprenorphine. Ms. LaBelle has served as a member of the Scientific Study (Study Section) Review Committee for the National Institute on Drug Abuse. Since 2004, she has served on the National Advisory Committee on Buprenorphine for the Health Resources and Services Administration and participated in professional editing of TAP 30 Technical Assistance Publication for Nurses with SAMHSA, 2009. Co-author : Five Year Experience with Collaborative Care of Opioid Addicted Patients using Buprenorphine in Primary Care, published Archives of Internal Medicine. In May 2011 she was the recipient of Individual Leadership Award, for Innovation In Health Care from MA Bureau of Substance Abuse Services as well as a NIATX award recipient 2011 Innovations in Behavioral Health Services award for Process Improvements. She is a board member of the Addiction Nurses Certification Board, and recently started a MA Chapter for addiction nurses.
Sharon Levy
MD, MPH
Sharon Levy, MD, MPH, is a board certified Developmental-Behavioral Pediatrician and an Assistant Professor of Pediatrics at Harvard Medical School; she also has a Master's degree from the Harvard School of Public Health. She is the Director of the Adolescent Substance Abuse Program in the Divi-sion of Developmental Medicine at Boston Children's Hospital where she has evaluated and treated hundreds of adolescents with substance use disorders. She has published extensively on the outpatient management of substance use disorders in adolescents, including screening and brief advice in primary care, the use of drug testing and the outpatient management of opioid de-pendent adolescents. She is the PI of the SAMHSA-funded medical residen-cy SBIRT project at Children's Hospital Boston and an NIAAA-funded study validating the youth alcohol screening tool in a population of youth with chronic medial illness. Dr. Levy currently serves as the chair of the American Academy of Pediatrics Committee on Substance Abuse.
Paula Lum
MD, MPH, FASAM
Dr. Lum is a general internist and primary care physician, and Professor of Medicine in the HIV/AIDS Division in the University of California, San Francisco's Department of Medicine at San Francisco General Hospital. She is certified by the American Boards of Internal Medicine and Addiction Medicine.
Kelley Saia
MD
Kelley Saia, MD, is an attending obstetrician in the Department of Obstetrics and Gynecology at Boston Medical Center and an Assistant Professor of Obstetrics and Gynecology at Boston University School of Medicine.Dr. Saia received her medical degree from the University of Vermont, College of Medicine and completed her residency in obstetrics and gynecology at Boston Medical Center.
In addition to caring for women with general obstetrics and gynecologic issues, she is the director of Project RESPECT, Substance Use Disorder Treatment in pregnancy at Boston Medical Center. Project RESPECT has been caring for pregnant women with substance use disorder for over 30 years and Dr. Saia, established the first obstetric buprenorphine clinic in the greater Boston area in 2006. RESPECT cares for over 125 mother-baby pairs per year with a multidisciplinary team consisting of obstetricians, addiction medicine specialist, pediatrics, psychiatry, social work, lactation consultants and nursing. Dr. Saia is actively engaged in patient care QI, clinical and scientific research, community outreach and medical training.
Andrew Saxon
MD, FASAM
Andrew J. Saxon, M.D. Professor, Department of Psychiatry and Behavioral Sciences, University of Washington Director, Center of Excellence in Substance Abuse Treatment and Education, VA Puget Sound Health Care System Director, Addiction Psychiatry Residency Program, University of Washington Preceding his entry into psychiatry, Dr. Saxon completed an internal medicine internship and worked for 4 years as an emergency room physician. Subsequent to his general psychiatry residency at the University of Washington, Dr. Saxon has more than a quarter century of experience as a clinical and research addiction psychiatrist. Dr. Saxon is board certified with added qualifications in addiction psychiatry by the American Board of Psychiatry and Neurology. Dr. Saxon sits on the editorial boards of the journals, Drug and Alcohol Dependence and General Hospital Psychiatry. Dr. Saxon's current research work is supported by the VA, the Department of Defense, and the National Institute on Drug Abuse and involves pharmacotherapies and psychotherapies for alcohol, cocaine, tobacco, and opioid use disorders as well work in co-occurrence of substance use disorders and posttraumatic stress disorder and on reducing homelessness.
Alexander Y. Walley
MD, MSc, FASAM
Alexander Y. Walley, M.D., M.Sc., is an Assistant Professor of Medicine at Boston University School of Medicine, a general internist and addiction medicine specialist at Boston Medical Center. He does clinical and research-related work on the medical complications of substance use, specifically HIV and overdose. He provides primary care and office-based buprenorphine treatment for HIV patients at Boston Medical Center and methadone maintenance treatment at Community Substance Abuse Centers. He is the medical director for the Massachusetts Department of Public Health's Opioid Overdose Prevention Pilot Program. He is the Director of the Boston University Addiction Medicine Fellowship program.
CME Information and Disclosure Listing
Date of Release: July 2015
Approved Through: July 2018
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
The online enduring material will provide the required 8 hours needed to obtain the waiver to prescribe buprenorphine in office-based treatment of opioid use disorders.
This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.
In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
ASAM CME Committee
Name | Nature of Relevant Financial Relationship | ||
Commercial Interest | What was received? | For what role? | |
Adam J. Gordon, MD, MPH, FACP, FASAM, Chair | None | ||
Edwin A. Salsitz, MD, FASAM | None | ||
Herbert Malinoff, MD, FACP, FASAM | None | ||
Noel Ilogu, MD, MRCP | None | ||
Abigail Kay, MD | None | ||
John Tanner, DO, FASAM | Reckitt Benckiser OREXO BDSI | Honorarium Honorarium Honorarium | Speaker Speaker Speaker and Consultant |
Catherine Friedman, MD | None | ||
ASAM Buprenorphine Program Planning Committee
Name | Nature of Relevant Financial Relationship | ||
Commercial Interest | What was received? | For what role? | |
Dan Alford, MD, MPH | None | ||
Andrew J. Saxon, MD | UpToDate | Royalties | Section Editor, Drug Use Disorders |
Colleen LaBelle, BSN, RN-BC, CARN | None | ||
Edwin Salsitz, MD, FASAM | None | ||
Jeffrey D. Baxter, MD | None | ||
Kelley Saia, MD | None | ||
Sharon Levy, MD, MPH | None | ||
Paula J. Lum, MD, MPH | None | ||
ASAM Buprenorphine Course Faculty
Name | Nature of Relevant Financial Relationship | ||
Commercial Interest | What was received? | For what role? | |
Edwin Salsitz, MD, FASAM | None | ||
| R. Corey Waller, MD, MS, FACEP, DFASAM | None | ||
Andrew J. Saxon, MD | UpToDate | Royalties | Senior Editor, Drug Use Disorders |
Colleen LaBelle, BSN, RN-BC, CARN | None | ||
Dan A. Alford, MD, MPH | None | ||
Jeffrey D. Baxter, MD | None | ||
Kelley Saia, MD | None | ||
Sharon Levy, MD, MPH | None | ||
Paula J. Lum, MD, MPH | None | ||
Sarah Bagley, MD | ASAM Millennium Fellowship Award | Partial Salary Support | Awardee |
Alexander Y. Walley, MD, MSc | None | ||
ASAM CME Committee Reviewers
Name | Nature of Relevant Financial Relationship | |||
Commercial Interest | What was received? | For what role? | ||
Adam J. Gordon, MD, MPH, FACP, FASAM | None | |||
Herbert Malinoff, MD, FACP, FASAM | None | |||
When all 8 hours have been completed, CME can be claimed in the e-Learning Center.
Download this helpful FAQ for technical issues.
All other questions, contact ASAM Education.
education@ASAM.org | 301.656.3920
This program has been reviewed and is approved for a maximum of 8.00 AAPA Category 1 CME credits by the PA Review Panel. Approval is valid for one year from the issue date of 01/01/2017 . Participants may submit the post-test at any time during that period.
This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
Successful completion of the post-test is required to earn AAPA Category 1 CME credit. Successful completion is defined as a cumulative score of at least 70 percent correct.
Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs and PAs from prescribing these medications even if Federal law allows it.
Apply
- Fill out the Waiver Notification Form on SAMHSA’s website.
- Submit copies of your training certificate(s) to SAMHSA by email: infobuprenorphine@samhsa.hhs.gov or fax: 301.576.5237.
SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.
Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.
If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.
Qualify
To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:
- Be licensed under state law to prescribe schedule III, IV, or V medications for pain
- Complete no less than 24 hours of appropriate education through a qualified provider or through other training or experience, demonstrate the ability to treat and manage OUD
- If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.
Key:
Complete
Next
Failed
Available
Locked